Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company, announced its financial results for the year ended December 31, 2025, marking a significant transition to a commercial stage with the FDA approval of PAPZIMEOS, the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The company reported total revenues of $9.7 million, a substantial increase from $3.9 million in the previous year, primarily driven by the launch of PAPZIMEOS, which generated $3.4 million in net product revenue in the fourth quarter of 2025. The company also highlighted the assignment of a permanent J-code for PAPZIMEOS by the Centers for Medicare and Medicaid Services, effective April 1, 2026, which is expected to streamline the claims process and enhance patient access. Additionally, Precigen's cash, cash equivalents, and investments totaled $100.4 million as of December 31, 2025, providing a solid foundation to fund operations towards cash flow break-even by the end of 2026. The company is optimistic about the ongoing momentum in the first quarter of 2026, with strong demand for PAPZIMEOS and expanding payer coverage now estimated to cover approximately 215 million lives across the U.S. The company plans to discuss further updates during its upcoming conference call.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.